OBJECT FOR THE REQUEST: Ex-vivo study on therapeutic efficacy of three YKL40 inhibitors and reference compound on cell and tissue IPF models.
After collecting all the information regarding the request for proposal and after analyzing the completeness of the offers, the Commission concludes that the most advantageous offer meeting all the requirements contained in the request has presented:
Ludwig Boltzmann Gesellschaft GmbH
Neue Stiffingtalstraße 6/VI
8010 Graz, Austria
Total net price of the order execution: 70 000,00 EUR (318 479,00 PLN)
The Commission recommends the Management Board to perform the order in accordance with the offer submitted by Ludwig Boltzmann Gesellschaft GmbH.